Long-term tolerability and efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis

Trial Profile

Long-term tolerability and efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2013

At a glance

  • Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms GROWTH96
  • Most Recent Events

    • 30 Oct 2013 Tolerability results from a pooled analysis presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 26 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top